CIK: 0002013341 · Show all filings
Period: Q3 2025 (← Previous) (Next →)
Filing Date: Nov 14, 2025
Total Value ($000): $258,867 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 2,221,474 | $89,481 | 34.6% | $34.21 | -15.0% | COM | 156944100 |
| RAPT | RAPT Therapeutics, Inc. | 1,562,500 | $40,297 | 15.6% | $7.63 | +71.5% | COM | 75382E208 |
| CNTA | Centessa Pharmaceuticals plc | 1,314,019 | $31,865 | 12.3% | $17.10 | — | SPONSORED ADS | 152309100 |
| VSTM | Verastem, Inc. | 2,615,120 | $23,092 | 8.9% | $6.87 | +8.4% | COM | 92337C203 |
| ALMS | ALUMIS INC. | 4,247,670 | $16,948 | 6.5% | $9.97 | -58.7% | COM | 022307102 |
| DNLI | Denali Therapeutics Inc. | 1,000,000 | $14,520 | 5.6% | $14.37 | 0.0% | COM | 24823R105 |
| CRVS | Corvus Pharmaceuticals, Inc. | 1,731,233 | $12,759 | 4.9% | $7.13 | -28.3% | COM | 221015100 |
| — | Akero Therapeutics, Inc. | 244,900 | $11,628 | 4.5% | $27.82 | — | COM | 00973Y108 |
| KYMR | Kymera Therapeutics, Inc. | 146,332 | $8,282 | 3.2% | $45.17 | -0.1% | COM | 501575104 |
| HNGE | Hinge Health, Inc. | 135,000 | $6,626 | 2.6% | $40.42 | +29.4% | CL A | 433313103 |
| RNAM | Avidity Biosciences, Inc. | 40,000 | $1,743 | 0.7% | $29.81 | +35.6% | COM | 05370A108 |
| CASIF | CASI Pharmaceuticals, Inc. | 979,956 | $1,627 | 0.6% | $4.16 | -57.1% | ORD SHS | G1933S101 |